513 articles with Evotec AG
Evotec SE announced that the Company has launched an initiative for pandemic preparedness.
Celmatix’s drug program works by mimicking anti-Mullerian hormone, which acts as the molecular break that keeps women from depleting their ovarian reserves too quickly.
Evotec SE announced the financial results and corporate updates for the first quarter 2021.
Evotec SE will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021.
Evotec and the GCKD Study Enter into Strategic Collaboration to Build A Unique Molecular Patient Database
Evotec SE and the University Hospital Erlangen announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease cohort study.
Bristol Myers Squibb Exercises Option to Extend Targeted Protein Degradation Partnership with Evotec
Evotec SE announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation.
Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse
Evotec SE announced that the Company has initiated the construction of its J.POD 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France.
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE, a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate.
Evotec SE announced that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company.
Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
Evotec SE announced that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company.
Evotec SE announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials.
Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2020.
Evotec SE announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
Evotec and Chinook Therapeutics Enter Into Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
Evotec SE and Chinook Therapeutics, Inc. announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases.
Evotec SE announced that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.
Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure
Evotec SE announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.
Evotec announced that Dr Cord Dohrmann has been appointed to the German Council of Science and Humanities for a term of three years.
Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation
Evotec SE announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development.
Just - Evotec Biologics Expands Contract with the Department of Defense for Manufacturing of Monoclonal Antibodies
Evotec SE announced that the U.S. Department of Defense awarded its Seattle, Washington-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies for use in the development of a treatment and/or prophylaxis for COVID-19.
Evotec SE announced that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021: